

## Changes in Lyme neuroborreliosis incidence in Denmark, 1996 to 2015

Tetens, Malte M; Haahr, Rasmus; Dessau, Ram B; Krogfelt, Karen A; Bodilsen, Jacob; Andersen, Nanna S; Møller, Jens K; Roed, Casper; Christiansen, Claus B; Ellermann-Eriksen, Svend; Bangsberg, Jette M.; Hansen, Klaus; Benfield, Thomas L; Andersen, Christian Ø.; Obel, Niels; Omland, Lars H; Lebech, Anne-Mette

*Published in:*

Ticks and Tick-borne Diseases

*DOI:*

[10.1016/j.ttbdis.2020.101549](https://doi.org/10.1016/j.ttbdis.2020.101549)

*Publication date:*

2020

*Document Version*

Peer reviewed version

*Citation for published version (APA):*

Tetens, M. M., Haahr, R., Dessau, R. B., Krogfelt, K. A., Bodilsen, J., Andersen, N. S., Møller, J. K., Roed, C., Christiansen, C. B., Ellermann-Eriksen, S., Bangsberg, J. M., Hansen, K., Benfield, T. L., Andersen, C. Ø., Obel, N., Omland, L. H., & Lebech, A.-M. (2020). Changes in Lyme neuroborreliosis incidence in Denmark, 1996 to 2015. *Ticks and Tick-borne Diseases*, 11(6), Article 101549. <https://doi.org/10.1016/j.ttbdis.2020.101549>

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### Take down policy

If you believe that this document breaches copyright please contact [rucforsk@kb.dk](mailto:rucforsk@kb.dk) providing details, and we will remove access to the work immediately and investigate your claim.

1 **Title:** Changes in Lyme neuroborreliosis incidence in Denmark, 1996 to 2015

2

3 **Authors:** Malte M. Tetens<sup>1</sup>, Rasmus Haahr<sup>1</sup>, Ram B. Dessau, M.D.<sup>2</sup>, Karen A. Krogfelt, Ph.D.<sup>3,4</sup>,  
4 Jacob Bodilsen, M.D.<sup>5,6</sup>, Nanna S. Andersen, Ph.D.<sup>7</sup>, Jens K. Møller, D.M.Sc.<sup>8</sup>, Casper Roed,  
5 Ph.D.<sup>1</sup>, Claus B. Christiansen, Ph.D.<sup>9</sup>, Svend Ellermann-Eriksen, D.M.Sc.<sup>10</sup>, Jette M. Bangsborg,  
6 D.M.Sc.<sup>11</sup>, Klaus Hansen, D.M.Sc.<sup>12</sup>, Thomas L. Benfield, D.M.Sc.<sup>13,14</sup>, Christian Østergaard  
7 Andersen, D.M.Sc.<sup>15</sup>, Niels Obel, D.M.Sc.<sup>1,14</sup>, Lars H. Omland, D.M.Sc.<sup>1</sup>, Anne-Mette Lebech,  
8 D.M.Sc.<sup>1,14</sup>

9

## 10 **Affiliations**

11 1. Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet,  
12 Copenhagen, Denmark

13 2. Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark

14 3. Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Denmark

15 4. Department of Natural Sciences and Environment, Roskilde University, Denmark

16 5. Departments of Clinical Microbiology, Aalborg University hospital, Aalborg, Denmark

17 6. Departments of and Infectious Diseases, Aalborg University hospital, Aalborg, Denmark

18 7. Clinical Centre for Emerging and Vector-borne Infections, Odense University Hospital, Odense,  
19 Denmark

20 8. Department of Clinical Microbiology, Vejle Hospital, Vejle, Denmark

21 9. Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet,  
22 Copenhagen, Denmark

23 10. Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark

24 11. Department of Clinical Microbiology, Herlev University Hospital, Copenhagen, Denmark

25 12. Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen,  
26 Denmark

27 13. Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark

28 14. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of  
29 Copenhagen, Copenhagen, Denmark

30 15. Department of Clinical Microbiology, Hvidovre University Hospital, Copenhagen, Denmark

31

32

33 **Corresponding author**

34 Malte Mose Tetens, Bachelor of Medical Sciences

35 Department of Infectious Diseases

36 Copenhagen University hospital

37 Blegdamsvej 9

38 DK-2100 Copenhagen Ø

39 Denmark

40 Phone: +45 25 68 72 03

41 E-mail: malte.mose.tetens.01@regionh.dk

42

43 Word count (abstract): 237

44 Word count (manuscript): 3,071

45 Tables: 1

46 Figures: 3

47

48 **Keywords (max 6):** surveillance; epidemiology; *Borrelia burgdorferi* sensu lato.

49 **Declaration of Competing Interest:** K. Hansen has received royalties from Thermo Fisher; R.

50 Dessau participated in advisory board meeting Roche Diagnostics 2018 outside this work; all other

51 authors declare no conflicts of interests and no support from any organization for the submitted

52 work.

53 **Local Ethics Committee approval:** The study was approved by the Danish Data Protection

54 Agency and the National Board of Health (RH-2015-285, I-Suite no.: 04297). An approval from the

55 local Ethics Committee is not needed for this type of study in Denmark.

56

57 **ABSTRACT**

58 Lyme neuroborreliosis (LNB) has recently been added to the list of diseases under the European  
59 Union epidemiological surveillance in order to obtain updated information on incidence. The goal  
60 of this study was to identify temporal (yearly) variation, high risk geographical regions and risk  
61 groups, and seasonal variation for LNB in Denmark.

62 This cohort-study investigated Danish patients (n= 2,791) diagnosed with LNB  
63 (defined as a positive *Borrelia burgdorferi* sensu lato (s.l.) intrathecal antibody test) between 1996-  
64 2015. We calculated incidence and incidence ratios of LNB by comparing 4-yr groups of calendar-  
65 years, area of residency, sex and age, income and education groups, and the number of new LNB  
66 cases per month.

67 The incidence of LNB was 2.2 per 100,000 individuals and year in 1996-1999, 2.7 in  
68 2004-2007 and 1.1 per 100,000 individuals in 2012-2015. Yearly variations in LNB incidence were  
69 similar for most calendar-year groups. LNB incidence was highest in Eastern Denmark and among  
70 males and individuals who were 0-14 yrs old, who had a yearly income of >449,000 DKK, and who  
71 had a Master's degree or higher education. The number of LNB cases was highest from July to  
72 November ( $p < 0.001$ ).

73 In conclusion, based on Danish nationwide data of patients with positive *B.*  
74 *burgdorferi* s.l. intrathecal antibody index (1996-2015) the incidence of LNB was found to increase  
75 until 2004-2007 but thereafter to decline. European surveillance studies of Lyme borreliosis should  
76 be encouraged to monitor the incidence trend.

77

78 **1. INTRODUCTION**

79                   Lyme borreliosis, a tick-borne disease caused by the spirochetes of the *Borrelia*  
80 *burgdorferi* sensu lato (s.l.) complex is the most prevalent vector-borne infection in Europe (Stanek  
81 et al., 2012). Due to climatic and environmental changes, the incidence of tick-borne disease is  
82 expected to increase, and it has been suggested that Lyme borreliosis will become a more prominent  
83 health concern. However, as it is recognized that surveillance across European countries is  
84 heterogenous Lyme neuroborreliosis (LNB) has since 2018 been included on the list of diseases  
85 under the European Union epidemiological surveillance by the European Commission (The Lancet,  
86 2018) in order to achieve more comprehensive information of the incidence of Lyme borreliosis at  
87 the European level.

88                   In Denmark LNB has been a mandatory clinical notifiable disease since 1991.  
89 However, laboratory-based surveillance based on positive tests for *B. burgdorferi* s.l. intrathecal  
90 antibody index with electronic data-transfer has been shown to be more complete than surveillance  
91 based on manually processed notification and the hospital discharge databases registers (Dessau et  
92 al., 2015; Septfons et al., 2019). Furthermore, studies of surveillance of LNB based on positive test  
93 for *B. burgdorferi* s.l. intrathecal antibody index only reported a low risk of including misclassified  
94 cases (Dahl et al., 2019; Hansen and Lebech, 1992).

95                   Potential changes in LNB incidence over time (years) in Denmark remains  
96 uninvestigated. Further identification of groups at risk for acquiring LNB will be of interest to the  
97 public and health care providers. We used an established Danish nationwide cohort of patients with  
98 LNB to investigate temporal changes in LNB incidence over time and to investigate whether LNB  
99 incidence differ according to geography, age, sex, or socioeconomic factors. Lastly, we investigated  
100 the seasonal variations of LNB incidence.

## 101 2. METHODS

### 102 2.1 Setting and data sources

103 In the years of study inclusion, Denmark had a population of 5.2 million to 5.7 million  
104 individuals (*Statbank Denmark*, 2019). Tax-supported health care is provided free of charge to all  
105 Danish residents (Schmidt et al., 2019). The unique 10-digit personal identification number  
106 assigned to all Danish residents at birth or upon immigration was used to track individuals in the  
107 Danish national health and administrative registries (Schmidt et al., 2019). Data on *B. burgdorferi*  
108 s.l. intrathecal antibody index were extracted from data files obtained from the Danish Departments  
109 of Microbiology laboratories that performed this test (see Supplementary Appendix). Additional  
110 data were extracted from the Danish Civil Registration system, the Building and Housing Register,  
111 the Income Statistics Register and the Danish Educational Attainment Registry (see Supplementary  
112 Appendix). We extracted data on the general Danish population numbers according to calendar-  
113 year, municipality of residence, sex, age, yearly income and highest educational attainment from  
114 Statistics Denmark (see Supplementary Appendix).

115

### 116 2.2 Study population

117 *LNB patient cohort:* We identified all Danish residents with a positive test for *B.*  
118 *burgdorferi* s.l. intrathecal antibody index during the period between 1 January 1996 and 31  
119 December 2015, based on data files obtained from all Danish Departments of Microbiology that  
120 performed the test during the time period. *B. burgdorferi* s.l. intrathecal antibody index was  
121 measured by capture enzyme-linked immunosorbent assays (ELISA) that uses native purified  
122 flagellum from *Borrelia* (strain DK1) as antigen (Hansen and Lebech, 1991). The antibody index  
123 had been calculated using the formula:  $(OD_{csf}/OD_{serum}) * (OD_{csf} - OD_{serum})$ , with  $OD_{csf}$  and  
124  $OD_{serum}$  representing the optical density in cerebrospinal fluid (CSF) and sera, respectively. An  
125 antibody index  $\geq 0.3$  is regarded as positive.

126 Inclusion date for LNB patients was the date of lumbar puncture. The Danish cohort  
127 of LNB patients and methodology for testing has been described previously (Haahr et al., 2019;  
128 Obel et al., 2018).

129

### 130 2.3 Statistical analysis

131 *Incidence – temporal changes*

132 To investigate LNB changes over time (years) we grouped Danish resident and LNB  
133 patients according to calendar-year (1996-1999, 2000-2003, 2004-2007, 2008-2011, and 2012-  
134 2015). For each of these calendar year-periods, we divided the number of LNB cases with the  
135 number of inhabitants at risk at 1 January to estimate the average yearly incidence and incidence  
136 ratio (IR) and corresponding 95% confidence interval (CI), with the calendar year-period with the  
137 lowest incidence serving as reference. We further examined whether LNB changed over time in the  
138 demographic subgroups represented by geographical area of residence (East Zealand, North  
139 Zealand, Southwest Zealand, Funen, South Jutland, Mid Jutland, Northwest Jutland, North Jutland  
140 or Bornholm), sex (male or female), age (0-<15 years, 15-<30 years, 30-<45 years, 45-<60 years or  
141  $\geq 60$  years), yearly income (<150,000 DKK, 150,000-<250,000 DKK, 250,000-<450,000 DKK or  $\geq$   
142 450,000 DKK) and highest educational attainment (less than Bachelor's degree, Bachelor's degree  
143 or higher than Bachelor's degree). The geographical areas were defined according to municipalities  
144 (see Supplementary Table 1 and Supplementary Figure 1).

145

#### 146 Incidence - demographic

147 Danish residents and LNB patients were grouped according to geographical area of  
148 residence, sex, age, yearly income and highest educational attainment. We identified the total  
149 number of Danish residents at risk at 1 January each year between 1996-2015 according to  
150 geographical area of residency, sex, age, yearly income and educational level. We divided the total  
151 number of LNB cases between 1996-2015 with the total number of inhabitants at risk at 1 January  
152 every year between 1996-2015 according to geographical area of residency, sex, age, yearly income  
153 and highest educational attainment to estimate average yearly incidence and IR and corresponding  
154 95% CI with the category with the lowest incidence serving as reference.

155

#### 156 Incidence – seasonal variation

157 We calculated the number of LNB patients with inclusion dates defined as the date of  
158 lumbar puncture with a positive intrathecal antibody index test for each calendar-month to estimate  
159 the number of new LNB cases per calendar-month. We ascertained difference in LNB incidence  
160 between calendar-months and performed a chi-square test to investigate for statistical differences  
161 with a significance level of  $p < 0.05$ . We used SPSS Statistics, version 25 (SPSS, Inc., Chicago,  
162 Illinois, USA) and R version 3.5.1 for all analysis.

163

164 **2.4 Regulatory compliance**

165                   The study was approved by the Danish Data Protection Agency and the National  
166 Board of Health (RH-2015-285, I-Suite no.: 04297). An approval from the local Ethics Committee  
167 is not needed for this type of study in Denmark.

168



169 **3. RESULTS**

170 We identified a total of 2,791 LNB patients with a first-time positive test for *B.*  
171 *burgdorferi* s.l intrathecal antibody index between 1 January 1996 and 31 December 2015. The  
172 average incidence for the entire study period was 2.6 per 100,000 individuals per year. The median  
173 age of LNB patients was 45.8 years and the proportion of males was 56.8 % (Table 1).

174

175 3.1 Incidence – temporal changes

176 The incidence of LNB increased nationwide from the calendar year-period 1996-1999  
177 (2.2 LNB cases per 100,000 individuals per year) to 2004-2007 (3.3 LNB cases per 100,000  
178 individuals per year), but thereafter declined to 1.8 LNB cases per 100,000 individuals per year  
179 during 2012-2015 (Table 1 and Figure 1). The incidence of LNB increased until 2004-2007 but  
180 thereafter declined with time for most geographical areas of residency and irrespective of sex, age,  
181 yearly income or educational level (Figure 2, Supplementary Figure 2, Supplementary Figure 3,  
182 Supplementary Figure 4 and Supplementary Figure 5).

183

184 3.2 Incidence – demographic

185 As shown in Table 1, higher average incidence of LNB was observed in North  
186 Zealand, Southwest Zealand, Funen and Bornholm compared with the area with the lowest  
187 incidence of LNB (South Jutland). The average incidence of LNB was higher in males (3.0 LNB  
188 cases per 100,000 individuals per year) compared with females (2.2 LNB cases per 100,000  
189 individuals per year) corresponding to an IR of 1.3, 95% CI: 1.2 to 1.4 (Table 1). Moreover, the  
190 average incidence of LNB was higher in individuals aged 0-<15 years (4.2 LNB cases per 100,000  
191 individuals per year, IR 5.4, 95% CI: 4.5 to 6.3), 45-<60 years (2.9 LNB cases 100,000 individuals  
192 per year, IR 3.7, 95% CI: 3.1 to 4.3) and 60 years or older (3.3 LNB cases per 100.00 individuals  
193 per year, IR 4.2, 95% CI: 3.5 to 5.0) compared to people aged 15-<30 years (0.8 LNB cases per  
194 100,000 individuals per year) (Table 1).

195 With regards to annual income, the average incidence of LNB was highest in  
196 individuals with a yearly income of 450,000 DKK or more (3.3 LNB cases 100,000 individuals per  
197 year) compared with individuals with a yearly income between 150,000-<250,000 DKK (2.1 LNB  
198 cases per 100,000 individuals per year), corresponding to an IR of 1.6, 95% CI: 1.3 to 1.8 (Table 1).  
199 Finally, the average incidence of LNB was higher in individuals with a higher educational  
200 attainment than a bachelor's degree (3.3 cases per 100,000 individuals per year) compared with

201 individuals with less than a bachelor's degree (2.1 LNB cases per 100,000 individuals per year),  
202 corresponding to an IR of 1.6, 95% CI: 1.3 to 1.9 (Table 1).

203

### 204 3.3 Incidence - seasonal variation

205 We observed a monthly variation with the lowest number of new cases of LNB in  
206 March (2.8 cases of LNB/month) and the highest number of new cases in August (26.6 cases of  
207 LNB/month) ( $p < 0.0001$ ) (Figure 3).

208

209

210 **4. DISCUSSION**

211 Our study on LNB using nationwide data of positive *B. burgdorferi* s.l. intrathecal  
212 antibody index (1996-2015) provides an updated overview of the epidemiology of LNB in Denmark  
213 and documents that the incidence of LNB has increased until 2004-2007 but thereafter declined.

214  
215 The overall incidence of LNB in Denmark between 1996-2015 was 2.6 per 100,000  
216 individuals per year. This was of the same magnitude as has been estimated in earlier studies from  
217 Denmark as well as in Belgium but higher than in Germany and France (Enkelmann et al., 2018;  
218 Geebelen et al., 2019; Septfons et al., 2019). The incidence was however half the IR described from  
219 the neighboring country Sweden that reported an overall incidence of 6.3 per 100,000 for 2014. As  
220 the Swedish incidence data also was based on positive *B. burgdorferi* s.l. intrathecal antibody index  
221 cases with the national microbiology database our data seems comparable to their data. (Dahl et al.,  
222 2019; Knudtzen et al., 2017). The variation in incidences could be due to differences in prevalence  
223 of *B. burgdorferi* s.l. in the tick *Ixodes ricinus*, climate and biomes as well as number of people  
224 residing or working in areas endemic for Lyme borreliosis (Strnad et al., 2017). However,  
225 comparisons between countries must in general be interpreted with caution due to heterogeneity  
226 among surveillance systems which impact the estimates.

227 The incidence of LNB is likely to differ across European countries, possibly  
228 depending on differences in geographical factors, presence and abundance of ticks, distribution of  
229 the neurotropic genospecies *Borrelia garinii* as well as differences in human behavior influencing  
230 risk of tick exposure. Comparison of incidences of LNB between European countries is however  
231 difficult as surveillance of LNB is based on different methods of data collection: physician  
232 reporting, hospital diagnoses or laboratory surveillance. We used laboratory data of positive *B.*  
233 *burgdorferi* s.l. intrathecal antibody index as measure for LNB cases, as this previously has been  
234 shown to be more accurate as physician reporting or hospital discharge diagnosis (Dessau et al.,  
235 2015; Septfons et al., 2019).

236 Using this measure, we observed an increasing incidence of LNB in Denmark from 1996-1999 to  
237 2004-2007, but thereafter the incidence declined until the last study period 2012-2015 except for in  
238 two geographical areas. In agreement, no increase in LNB incidence was observed in France  
239 between 2005-2016 (Septfons et al., 2019) or Sweden between 2002-2014, but there were increases  
240 in a specific Swedish region between 2000-2005 (Henningson et al., 2010; Södermark et al., 2017).  
241 Furthermore, the incidence of Lyme borreliosis was reported to increase in eastern Germany

242 between 2002-2006 but decreased overall between 2009-2012 and did not increase between 2013-  
243 2017 (Enkelmann et al., 2018; Fülöp and Poggensee, 2008; Wilking and Stark, 2014). Changes in  
244 Lyme borreliosis incidence may also be influenced by improved awareness which could lead to a  
245 decrease in the number of patients that develop LNB and other disseminated manifestations of  
246 Lyme borreliosis. The Danish physicians may be increasingly aware of early symptoms of Lyme  
247 borreliosis and therefore promptly initiate antibiotic therapy. Also, the Danish population may have  
248 become increasingly informed of the importance of daily checks for ticks, prompt removal of ticks  
249 after exposure to avoid infection and recognizing erythema migrans especially in highly endemic  
250 areas (Jepsen et al., 2019). Therefore, our results due not necessarily reflect the overall national  
251 trend of Lyme borreliosis manifestations during the study period.

252 Identification of possible high incidence areas for acquiring LNB will be of interest to  
253 the public and health care professionals. We observed a significant variation in LNB incidence  
254 according to geographical area. The geographical distribution of LNB was in agreement with an  
255 estimated distribution of *I. ricinus* in Denmark as well as an estimate of incidence of *Borrelia*  
256 seropositivity among roe deer (Skarphéðinsson et al., 2005).

257 In agreement with other studies we found an increased incidence of LNB in males  
258 (Dahl et al., 2019; Enkelmann et al., 2018; Hansen and Lebech, 1992; Södermark et al., 2017).  
259 However, erythema migrans was reported to be more common in females than males (Enkelmann et  
260 al., 2018). Females have been observed to use protective practices against ticks more often than  
261 males (Jepsen et al., 2019). Males could also be less likely to notice early signs of Lyme disease  
262 compared with females. This would lead males to develop late-stage manifestations of *B.*  
263 *burgdorferi* s.l. infection such as LNB more often than females.

264 We observed a U-shaped incidence distribution with incidence being highest in  
265 children younger than 15 yr and individuals 60 yr or older as also described by others (Dahl et al.,  
266 2019; Dessau et al., 2015; Septfons et al., 2019; Wilking and Stark, 2014). The observation may  
267 partly be explained by more intense radicular pains in middle-age and elderly patients compared  
268 with younger adults leading to hospital admission (Hansen and Lebech, 1992). It has also been  
269 suggested that young adult individuals are more likely to have a subclinical infection with the  
270 neurotropic genospecies *B. garinii* (Carlsson et al., 2018) with less prominent radiculitic pain and  
271 rarely signs of meningism. Therefore, it is possible that the actual incidence of individuals infected  
272 with *B. burgdorferi* s.l. especially in this age-group is under-recognized. Explanations for the  
273 differences between age groups could also be related to differences in outdoor activity and leisure

274 time activities between age groups. Our estimated LNB incidence for children was slightly lower  
275 than incidence of LNB in children in the two Scandinavian countries Norway and Sweden  
276 (Henningsson et al., 2010; Øymar and Tveitnes, 2009) but comparable to another study from  
277 Sweden including 548 children with LNB from Gothenburg and surrounding municipalities  
278 (Södermark et al., 2017).

279 We observed a proportional increase in LNB incidence with increasing income with  
280 the highest yearly earners having the highest incidence of LNB. This is in agreement with American  
281 studies on other socioeconomic factors such as race and education (Moon et al., 2019; Springer and  
282 Johnson, 2018). An increased LNB incidence for individuals with higher attained education was  
283 observed in agreement with studies from North America (Springer and Johnson, 2018). Income and  
284 educational level would be expected to be correlated, and the high incidence of LNB in groups with  
285 either high income or high education level, could likely be explained by this correlation.  
286 Since infection is correlated with tick exposure, this variability in incidence rates among age groups  
287 and education achievements could very likely be due to differences in outdoor activities.

288 A seasonal variation in the monthly incidence of LNB with the incidence being  
289 highest between July and November was found and thus a close association of the seasonal activity  
290 of *I. ricinus* and the onset of LNB. This agrees with other studies on the seasonal variation of LNB  
291 in Denmark (Dessau et al., 2015; Hansen and Lebech, 1992) and other European countries  
292 (Enkelmann et al., 2018; Septfons et al., 2019) as well as studies on seasonal and climatic variation  
293 in *I. ricinus* activity (Brugger et al., 2018; Lin et al., 2019; Lindgren et al., 2000).

294 The major strengths of the study are the large sample size and our ability to include all  
295 Danish citizens with a proven positive *B. burgdorferi* s.l. intrathecal antibody index test over a 20-  
296 yr-period. The registry-based design was hampered by lacking access to data on cerebrospinal fluid  
297 (CSF) leucocytes counts, as the presence of CSF pleocytosis would have substantiated the diagnosis  
298 of LNB further. Thus, we may have overestimated the LNB incidence. However, as a positive *B.*  
299 *burgdorferi* s.l. intrathecal antibody index has a high diagnostic sensitivity for LNB we assume a  
300 low rate of misclassification of LNB cases and thus this effect is likely to be very limited (Dessau et  
301 al., 2015; Hansen, 1994; Hansen and Lebech, 1992, 1991; Henningsson et al., 2014). Factors that  
302 may have led to underestimation of LNB incidence are the lack of inclusion of (i) patients with an  
303 early LNB that have not yet have developed specific *B. burgdorferi* s.l. intrathecal antibodies and  
304 (ii) patients diagnosed and treated on clinical presentation alone without CSF investigation. The  
305 observed changes in LNB incidence over the study period could be due to changes in clinical testing

306 practices as only positive *B. burgdorferi* s.l. intrathecal antibody index tests were used to estimate  
307 incidence of LNB. However, because the national clinical guidelines for testing and diagnosing  
308 LNB in Denmark recommend testing all suspected cases of LNB with a *B. burgdorferi* s.l. antibody  
309 index test and these guidelines have not changed during the time period covered by this study, it is  
310 unlikely that the changes in LNB incidence are due to changes in how LNB is diagnosed in  
311 Denmark (Dessau et al., 2014). Our analyses of geographical variation may be limited by the fact,  
312 that we only have access to information on place of residence, which is not necessarily the place of  
313 exposure to tick bites.

314

## 315 **5. CONCLUSION**

316 Based on a Danish nationwide cohort of patients with LNB defined by positive *B.*  
317 *burgdorferi* s.l. intrathecal antibody index and data from the Danish National registries, LNB  
318 incidence in Denmark increased from the time period 1996-1999 to 2004-2007 but thereafter  
319 declined until the last study time period in 2011-2015. The incidence of LNB was highest for  
320 individuals with residency in Eastern Denmark, males, children and individuals with high income  
321 and high educational attainment.

322

### 323 **Conflict of interest**

324 K. Hansen has received royalties from Thermo Fisher; R. Dessau participated in  
325 advisory board meeting Roche Diagnostics 2018 outside this work; all other authors declare no  
326 conflicts of interests and no support from any organization for the submitted work.

327

### 328 **Funding sources**

329 The study was sponsored by the Danish Council for Independent Research (grant  
330 number: 6110-0173B).

331

332

333

334 **References**

- 335 Brugger, K., Walter, M., Chitimia-Dobler, L., Dobler, G., Rubel, F., 2018. Forecasting next  
336 season's *Ixodes ricinus* nymphal density: the example of southern Germany 2018. *Exp.*  
337 *Appl. Acarol.* 75, 281–288. <https://doi.org/10.1007/s10493-018-0267-6>
- 338 Carlsson, H., Ekerfelt, C., Henningsson, A.J., Brudin, L., Tjernberg, I., 2018. Subclinical Lyme  
339 borreliosis is common in south-eastern Sweden and may be distinguished from Lyme  
340 neuroborreliosis by sex, age and specific immune marker patterns. *Ticks Tick Borne Dis.* 9,  
341 742–748. <https://doi.org/10.1016/j.ttbdis.2018.02.011>
- 342 Dahl, V., Wisell, K.T., Giske, C.G., Tegnell, A., Wallensten, A., 2019. Lyme neuroborreliosis  
343 epidemiology in Sweden 2010 to 2014: clinical microbiology laboratories are a better data  
344 source than the hospital discharge diagnosis register. *Euro Surveill.* 24.  
345 <https://doi.org/10.2807/1560-7917.ES.2019.24.20.1800453>
- 346 Dessau, R.B., Bangsberg, J., Hansen, K., Lebech, A., Sellebjerg, F., Skarphedinsson, S.,  
347 Østergaard, C., 2014. Lyme Borreliose: Klinik, diagnostik og behandling i Danmark. The  
348 Danish Microbiological Society, The Danish Society of Infectious Diseases & the Danish  
349 Neurological Society.
- 350 Dessau, R.B., Espenhain, L., Mølbak, K., Krause, T.G., Voldstedlund, M., 2015. Improving  
351 national surveillance of Lyme neuroborreliosis in Denmark through electronic reporting of  
352 specific antibody index testing from 2010 to 2012. *Euro Surveill.* 20.  
353 <https://doi.org/10.2807/1560-7917.es2015.20.28.21184>
- 354 Enkelmann, J., Böhmer, M., Fingerle, V., Siffczyk, C., Werber, D., Littmann, M., Merbecks, S.-S.,  
355 Helmeke, C., Schroeder, S., Hell, S., Schlotthauer, U., Burckhardt, F., Stark, K., Schielke,  
356 A., Wilking, H., 2018. Incidence of notified Lyme borreliosis in Germany, 2013-2017. *Sci*  
357 *Rep* 8, 14976. <https://doi.org/10.1038/s41598-018-33136-0>
- 358 Fülöp, B., Poggensee, G., 2008. Epidemiological situation of Lyme borreliosis in Germany:  
359 surveillance data from six Eastern German States, 2002 to 2006. *Parasitol. Res.* 103 Suppl 1,  
360 S117-120. <https://doi.org/10.1007/s00436-008-1060-y>
- 361 Geebelen, L., Van Cauteren, D., Devleeschauwer, B., Moreels, S., Tersago, K., Van Oyen, H.,  
362 Speybroeck, N., Lernout, T., 2019. Combining primary care surveillance and a meta-  
363 analysis to estimate the incidence of the clinical manifestations of Lyme borreliosis in  
364 Belgium, 2015-2017. *Ticks Tick Borne Dis.* 10, 598–605.  
365 <https://doi.org/10.1016/j.ttbdis.2018.12.007>
- 366 Haahr, R., Tetens, M.M., Dessau, R.B., Krogfelt, K.A., Bodilsen, J., Andersen, N.S., Møller, J.K.,  
367 Roed, C., Christiansen, C.B., Ellermann-Eriksen, S., Bangsberg, J.M., Hansen, K., Benfield,  
368 T.L., Østergaard Andersen, C., Obel, N., Lebech, A.-M., Omland, L.H., 2019. Risk of  
369 neurological disorders in patients with European Lyme neuroborreliosis. A nationwide  
370 population-based cohort study. *Clin. Infect. Dis.* <https://doi.org/10.1093/cid/ciz997>
- 371 Hansen, K., 1994. Lyme neuroborreliosis: improvements of the laboratory diagnosis and a survey of  
372 epidemiological and clinical features in Denmark 1985-1990. *Acta Neurol. Scand., Suppl.*  
373 151, 1–44.
- 374 Hansen, K., Lebech, A.M., 1992. The clinical and epidemiological profile of Lyme neuroborreliosis  
375 in Denmark 1985-1990. A prospective study of 187 patients with *Borrelia burgdorferi*  
376 specific intrathecal antibody production. *Brain* 115 ( Pt 2), 399–423.  
377 <https://doi.org/10.1093/brain/115.2.399>
- 378 Hansen, K., Lebech, A.M., 1991. Lyme neuroborreliosis: a new sensitive diagnostic assay for  
379 intrathecal synthesis of *Borrelia burgdorferi*-specific immunoglobulin G, A, and M. *Ann.*  
380 *Neurol.* 30, 197–205. <https://doi.org/10.1002/ana.410300212>

- 381 Henningsson, A.J., Christiansson, M., Tjernberg, I., Löfgren, S., Matussek, A., 2014. Laboratory  
382 diagnosis of Lyme neuroborreliosis: a comparison of three CSF anti-*Borrelia* antibody  
383 assays. *Eur. J. Clin. Microbiol. Infect. Dis.* 33, 797–803. [https://doi.org/10.1007/s10096-](https://doi.org/10.1007/s10096-013-2014-6)  
384 013-2014-6
- 385 Henningsson, A.J., Malmvall, B.-E., Ernerudh, J., Matussek, A., Forsberg, P., 2010.  
386 Neuroborreliosis--an epidemiological, clinical and healthcare cost study from an endemic  
387 area in the south-east of Sweden. *Clin. Microbiol. Infect.* 16, 1245–1251.  
388 <https://doi.org/10.1111/j.1469-0691.2009.03059.x>
- 389 Jepsen, M.T., Jokelainen, P., Jore, S., Boman, A., Slunge, D., Kroghfelt, K.A., 2019. Protective  
390 practices against tick bites in Denmark, Norway and Sweden: a questionnaire-based study.  
391 *BMC Publ. Health* 19, 1344. <https://doi.org/10.1186/s12889-019-7613-4>
- 392 Knudtzen, F.C., Andersen, N.S., Jensen, T.G., Skarphédinsson, S., 2017. Characteristics and  
393 clinical outcome of Lyme neuroborreliosis in a high endemic area, 1995-2014: A  
394 retrospective cohort study in Denmark. *Clin. Infect. Dis.* 65, 1489–1495.  
395 <https://doi.org/10.1093/cid/cix568>
- 396 Lin, S., Shrestha, S., Prusinski, M.A., White, J.L., Lukacik, G., Smith, M., Lu, J., Backenson, B.,  
397 2019. The effects of multiyear and seasonal weather factors on incidence of Lyme disease  
398 and its vector in New York State. *Sci. Total Environ.* 665, 1182–1188.  
399 <https://doi.org/10.1016/j.scitotenv.2019.02.123>
- 400 Lindgren, E., Tälleklint, L., Polfeldt, T., 2000. Impact of climatic change on the northern latitude  
401 limit and population density of the disease-transmitting European tick *Ixodes ricinus*.  
402 *Environ. Health Perspect.* 108, 119–123. <https://doi.org/10.1289/ehp.00108119>
- 403 Moon, K.A., Pollak, J., Hirsch, A.G., Aucott, J.N., Nordberg, C., Heaney, C.D., Schwartz, B.S.,  
404 2019. Epidemiology of Lyme disease in Pennsylvania 2006-2014 using electronic health  
405 records. *Ticks Tick Borne Dis.* 10, 241–250. <https://doi.org/10.1016/j.ttbdis.2018.10.010>
- 406 Obel, N., Dessau, R.B., Kroghfelt, K.A., Bodilsen, J., Andersen, N.S., Møller, J.K., Roed, C.,  
407 Omland, L.H., Christiansen, C.B., Ellermann-Eriksen, S., Bangsborg, J.M., Hansen, K.,  
408 Benfield, T.L., Rothman, K.J., Sørensen, H.T., Andersen, C.Ø., Lebech, A.-M., 2018. Long  
409 term survival, health, social functioning, and education in patients with European Lyme  
410 neuroborreliosis: nationwide population based cohort study. *BMJ* 361, k1998.  
411 <https://doi.org/10.1136/bmj.k1998>
- 412 Øymar, K., Tveitnes, D., 2009. Clinical characteristics of childhood Lyme neuroborreliosis in an  
413 endemic area of northern Europe. *Scand. J. Infect. Dis.* 41, 88–94.  
414 <https://doi.org/10.1080/00365540802593453>
- 415 Schmidt, M., Schmidt, S.A.J., Adelborg, K., Sundbøll, J., Laugesen, K., Ehrenstein, V., Sørensen,  
416 H.T., 2019. The Danish health care system and epidemiological research: from health care  
417 contacts to database records. *Clin. Epidemiol.* 11, 563–591.  
418 <https://doi.org/10.2147/CLEP.S179083>
- 419 Septfons, A., Goronflot, T., Jaulhac, B., Roussel, V., De Martino, S., Guerreiro, S., Launay, T.,  
420 Fournier, L., De Valk, H., Figoni, J., Blanchon, T., Couturier, E., 2019. Epidemiology of  
421 Lyme borreliosis through two surveillance systems: the national Sentinelles GP network and  
422 the national hospital discharge database, France, 2005 to 2016. *Euro Surveill.* 24.  
423 <https://doi.org/10.2807/1560-7917.ES.2019.24.11.1800134>
- 424 Skarphédinsson, S., Jensen, P.M., Kristiansen, K., 2005. Survey of tickborne infections in  
425 Denmark. *Emerg. Infect. Dis.* 11, 1055–1061. <https://doi.org/10.3201/eid1107.041265>
- 426 Södermark, L., Sigurdsson, V., Näs, W., Wall, P., Trollfors, B., 2017. Neuroborreliosis in Swedish  
427 children: A population-based study on incidence and clinical characteristics. *Pediatr. Infect.  
428 Dis. J.* 36, 1052–1056. <https://doi.org/10.1097/INF.0000000000001653>



- 429 Springer, Y.P., Johnson, P.T.J., 2018. Large-scale health disparities associated with Lyme disease  
430 and human monocytic ehrlichiosis in the United States, 2007-2013. PLoS ONE 13,  
431 e0204609. <https://doi.org/10.1371/journal.pone.0204609>
- 432 Stanek, G., Wormser, G.P., Gray, J., Strle, F., 2012. Lyme borreliosis. Lancet 379, 461–473.  
433 [https://doi.org/10.1016/S0140-6736\(11\)60103-7](https://doi.org/10.1016/S0140-6736(11)60103-7)
- 434 Statbank Denmark, <https://www.statistikbanken.dk/statbank5a/default.asp?w=1920> (Accessed 11  
435 October 2019).
- 436 Strnad, M., Hönig, V., Růžek, D., Grubhoffer, L., Rego, R.O.M., 2017. Europe-wide meta-analysis  
437 of *Borrelia burgdorferi* sensu lato prevalence in questing *Ixodes ricinus* ticks. Appl.  
438 Environ. Microbiol. 83. <https://doi.org/10.1128/AEM.00609-17>
- 439 The Lancet, 2018. Introducing EU-wide surveillance of Lyme neuroborreliosis [editorial]. Lancet  
440 392, 452. [https://doi.org/10.1016/S0140-6736\(18\)31738-0](https://doi.org/10.1016/S0140-6736(18)31738-0)
- 441 Wilking, H., Stark, K., 2014. Trends in surveillance data of human Lyme borreliosis from six  
442 federal states in eastern Germany, 2009-2012. Ticks Tick Borne Dis. 5, 219–224.  
443 <https://doi.org/10.1016/j.ttbdis.2013.10.010>
- 444
- 445
- 446
- 447

448 **TABLE 1:** Incidence and incidence ratio of Lyme neuroborreliosis (LNB) stratified on 4-yr time  
 449 periods, geography, sex, age, yearly income and highest attained education in Denmark, 1996-2015.

	<b>Number of LNB cases</b>	<b>Incidence of LNB per 100,000 individuals per year</b>	<b>Incidence rate ratio (95% confidence interval)</b>
<b>Calendar year-period</b>			
<i>1996-1999</i>	480	2.2	1.3 (1.1 to 1.4)
<i>2000-2003</i>	579	2.7	1.5 (1.3 to 1.7)
<i>2004-2007</i>	714	3.3	1.8 (1.6 to 2.1)
<i>2008-2011</i>	616	2.8	1.6 (1.4 to 1.8)
<i>2012-2015</i>	402	1.8	1 (Ref.)
<b>Geographical area</b>			
<i>East Zealand</i>	683	2.3	3.9 (2.7 to 5.7)
<i>North Zealand</i>	266	3.9	6.5 (4.4 to 9.7)
<i>Southwest Zealand</i>	420	3.6	6.2 (4.2 to 9.1)
<i>Funen</i>	409	4.2	7.1 (4.9 to 10.5)
<i>South Jutland</i>	28	0.6	1 (Ref.)
<i>Mid Jutland</i>	463	2.8	4.7 (3.2 to 6.9)
<i>Northwest Jutland</i>	26	0.6	1.1 (0.6 to 1.7)
<i>North Jutland</i>	425	1.8	3.0 (2.1 to 4.5)
<i>Bornholm</i>	71	8.2	14.0 (9.0 to 21.7)
<b>Sex</b>			
<i>Men</i>	1,584	3.0	1.3 (1.2 to 1.4)
<i>Women</i>	1,207	2.2	1.0 (Ref.)

450

451

452 **TABLE 1:** Continued

<b>Age (years)</b>			
<i>0-&lt;15</i>	826	4.2	5.4 (4.5 to 6.3)
<i>15-&lt;30</i>	157	0.8	1.0 (Ref.)
<i>30-&lt;45</i>	400	1.7	2.2 (1.8 to 2.6)
<i>45-&lt;60</i>	636	2.9	3.7 (3.1 to 4.3)
<i>&gt;=60</i>	772	3.3	4.2 (3.5 to 5.0)
<b>Yearly income*</b>			
<i>&lt; 150,000 DKK</i>	474	2.2	1.0 (0.9 to 1.2)
<i>150,000-&lt;250,000 DKK</i>	526	2.1	1.0 (Ref.)
<i>250,000-&lt;450,000 DKK</i>	662	2.4	1.1 (1.0 to 1.3)
<i>≥450,000 DKK</i>	257	3.3	1.6 (1.3 to 1.8)
<b>Highest attained education**</b>			
<i>Less than bachelor's degree</i>	1,179	2.1	1.0 (Ref.)
<i>Bachelor's degree</i>	322	3.2	1.5 (1.3 to 1.7)
<i>Higher than bachelor's degree</i>	148	3.3	1.6 (1.3 to 1.9)

453 \*Only individuals older than 20 years

454 \*\*Only individuals older than 20 years and younger than 70 years

455

456 **FIGURE 1:** Nationwide yearly Lyme neuroborreliosis (LNB) incidence per 100,000 individuals in  
457 Denmark

458

459 **FIGURE 2:** Yearly Lyme neuroborreliosis (LNB) incidence per 100,000 individuals by  
460 geographical area

461

462 **FIGURE 3:** Average number of new cases of Lyme neuroborreliosis (LNB) nationwide per month

463

464